2001-07-26
org.kosen.entty.User@fb50c4d
강지훈(kosen1)
발행기관
Harry Hnatyszyn, Ph.D. / Gunter K.Kraus, Ph.D.
발행일
1999/10/01
Telomerase expression has been associated with the immortality and metastasis of malignant breast cancer cells. Telomerase activity has been detected in several human cancers including breast carcinomas. However, telomerase activity is either very low or not detectable in normal cells of the body. These observations suggest the development of anti-telomerase strategies may prevent cancer cell divesion without adverse effects on normal cell populations. This investigation describes the development of a novel therapeutic approach directed against the telomerase complex required for cancer cell division. Catalytic RNA sequences, called ribozymes, will be expressed in breast cancer cell lines, to specifically recognize, cleave and eliminate the telomerase complex. This ribozyme therapy is designed to prevent tumor cell division and eliminate the metastatic potential of breast cancers. Retroviral vectors will deliver therapeutic genes encoding for the anati-telomerase ribozyme to breast cancer cells. These cells will be evaluated for anti-cancer ribozyme activity and for changes in cancer cell diveision to provide the basis for further development of this therapeutic approach in primary tumors from patients with malignant breast cancer. Gene therapy using ribozymes to eliminate cancer-causing molecules offers a promising strategy for the treatment of malgnant breast cancer.
-
리포트 평점
해당 콘텐츠에 대한 회원님의 소중한 평가를 부탁드립니다. -
0.0 (0개의 평가)